3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
15
Phase 1
7
Phase 1/2
6
Phase 3
3
Phase NA
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
6
Head and Neck Neoplasms
6
Lung Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Skin Neoplasms
2
Recurrence
2
Cholangiocarcinoma
2
Advanced Solid Tumor
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Squamous NSCLC
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Mouth Neoplasms
1
Mesothelioma
1
Liver Neoplasms
1
Laryngeal Neoplasms
1
Laryngeal Diseases
1
Klatskin Tumor
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hodgkin Disease
1
Hepatoblastoma
1
Interventions
Cisplatin
8
Radiotherapy
6
Fluorouracil
4
Paclitaxel
3
tislelizumab
2
nimotuzumab
2
Neoadjuvant Therapy
2
Esophagectomy
2
Drug Therapy
2
Capecitabine
2
spartalizumab
1
pembrolizumab
1
anlotinib
1
TP protocol
1
Surgical Procedures, Operative
1
Radiation
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Immunotherapy
1
Docetaxel
1
Clinical Trials, Phase II as Topic
1
Chemoradiotherapy
1
Cetuximab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Esophageal Squamous Cell Carcinoma
×
pembrolizumab
×
Clear all
NCT06907602
2025-04-02
ONTRESCC
Peking Union Medical College Hospital
Phase 2/3
Recruiting
120 enrolled